Russell Cohen (University of Chicago Medicine, Chicago, IL, US) spoke with touchIMMUNOLOGY around the optimal use of available therapies in the treatment of IBD. ‘Positioning Tofacitinib and Other Available Therapies’ was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021.
- Could you tell us a little about tofacitinib and its available formulations? (0:15)
- What key messages would you like to give to physicians regarding the optimal use of tofacitinib in the treatment of IBD? (0:57)
- What other JAK inhibitors are available or in clinical development for IBD? (1:56)
- What is the current status of S1P1 inhibitors in IBD and in which patients should they be considered? (2:54)
- Could you tell us a little about aprelimast and the potential of anti-phosphodiesterase therapy in IBD? (4:20)
Disclosures: Speaker’s Bureau for Abbvie and Takeda; Consultant / Advisory/ Scientific Advisory Board for Abbvie Laboratories, BMS/ Celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda and UCB Pharma; Clinical Trials /Grants (Principal Investigator; active) for Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Marc Ferratnte, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Marc Ferrante, UEG 2021: Risankizumab as a Maintenance Therapy for Crohn’s Disease
Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease. His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS […]
Marc Ferrante, UEG 2021: Unmet Needs in Managing Crohn’s Disease
It was a pleasure to discuss with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) the current unmet needs in the treatment of patients with Crohn’s disease. Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!